A clinical-grade wearable biosensor and an FDA-approved app based on technology developed for astronauts are being used by Canadian firm OTO to predict fertility treatment outcomes.

OTO Fertility, a digital health platform developed by OTO Coach, is using patented biometric data and AI-powered insights to predict fertility treatment outcomes. Designed to support patients and fertility clinics, the platform delivers precise data and personalised guidance that provide real-time clarity for paths to parenthood.

The core technology draws on 40 years of bioscience and space medicine, originally developed by Nasa for astronauts and later refined for elite athletes.

OTO’s offering includes a clinical-grade wearable biosensor and an FDA-approved app to help people understand their body signals, work with their body systems and actively support their fertility success. By monitoring more than fifty biometric markers such as heart rate variability, nervous system regulation and stress response, it identifies when the body is in an optimised fertility zone. The OTO Fertility Index is said to be a more accurate indicator of pregnancy success than the current standard of care measurements including age, BMI or AMH.

“Until now, there’s been no accurate way to predict fertility outcomes based on what’s actually happening in the body in real time,” said Caleb Evans, CEO of OTO. “Our solution gives patients a clear understanding of their body’s signals, restores agency and peace of mind, and provides clinicians with a powerful new layer of insights to guide better outcomes. OTO doesn’t replace existing fertility protocols, it enhances them. And for the millions who have done everything right and still struggle to get pregnant, it can help unlock a path forward.”

Globally, one in six women experience infertility and, despite technological advances, the success rate for IVF has stagnated. In fertility care, time is the one resource that cannot be replaced and missed opportunities come with an emotional, physical and financial burden that patients may carry for years. OTO Fertility wants to help patients and care providers reduce avoidable loss and poorly-timed interventions, and mitigate the risk of proceeding without critical physiological context.

The biosensor and Life app are available across North America at www.otofertility.com, with ongoing clinical programmes underway.

OTO Fertility is a division of OTO Coach (oto.coach), a biometric health intelligence company rooted in elite human performance science. Headquartered in Toronto with offices in Vancouver and Helsinki, OTO uses AI, clinical-grade biosensing and physiological research to deliver personalised insights across fertility, recovery and human performance.